Alnylam assumed with an Outperform at Raymond James

Raymond James assumed coverage of Alnylam (ALNY) with an Outperform rating and price target of $370, up from $308. The firm sees room for further share upside on commercial updates for the Amvuttra launch in coming quarters. The drug is well positioned for board uptake over the long term in transthyretin amyloid cardiomyopathy as the first-to-market TTR silencer, the analyst tells investors in a research note.